InvestSMART

The Hydration Pharmaceuticals Company Limited (ASX: HPC) - Share Price

- Current share price for HPC : $0.003

The Hydration Pharmaceuticals Company Limited (HPC) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It is a wholesale supplier and online retailer of Hydralyte products in North America. Following the divestiture of non-US assets to Prestige Consumer Healthcare Inc and associated subsidiaries, the Group has been focused on growing its predominately E-commerce US operations.

HPC General Information +

ASX Code HPC
Website http://www.hydralyte.com
Industry/Sector Personal Products
Market Cap ($M) 1
HPC Share Price $0.003
Day High $0.000
Day Low $0.000
Last Close $0.003
HPC Share Price Movement - ( No change )
Prices as at 16:40, 16 Oct 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

The Hydration Pharmaceuticals Company Limited (HPC) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from The Hydration Pharmaceuticals Company Limited (HPC) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

The Hydration Pharmaceuticals Company Limited (HPC) price-sensitive announcements

HPC - July and August 2026 Trading Update
The Hydration Pharmaceuticals Company Limited announced a July and August 2026 trading upd
The Hydration Pharmaceuticals Company Limited (HPC)
29 Sep 2026 | 8:52 AM
HPC - Q2 FY26 Quarterly Activities Report (App 4C)
The Hydration Pharmaceuticals Company Limited (Hydralyte USA) reported a solid improvement
The Hydration Pharmaceuticals Company Limited (HPC)
31 Jul 2026 | 2:14 PM
HPC - Capital raising, board renewal and management changes
The Hydration Pharmaceuticals Company Limited, trading as Hydralyte USA, announced a capit
The Hydration Pharmaceuticals Company Limited (HPC)
15 Jun 2026 | 9:35 AM
HPC - Reinstatement to Quotation
The Hydration Pharmaceuticals Company Limited (ASX: HPC) announced that its securities wil
The Hydration Pharmaceuticals Company Limited (HPC)
4 May 2026 | 9:25 AM

The Hydration Pharmaceuticals Company Limited (HPC) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
The Hydration Pharmaceuticals Company Limited (HPC)
ORDINARY FULLY PAID
 Consumer Staple $2 Results of Extraordinary General Meeting 8 Oct 2026 2:09PM $0.003 $0.003 fallen by 0%
The Hydration Pharmaceuticals Company Limited (HPC)
ORDINARY FULLY PAID
 Consumer Staple $2 July and August 2026 Trading Update 29 Sep 2026 8:52AM $0.003 $0.003 fallen by 0%
The Hydration Pharmaceuticals Company Limited (HPC)
ORDINARY FULLY PAID
 Consumer Staple $2 Letter to Shareholders regarding EGM 2 Sep 2026 10:27AM $0.003 $0.003 fallen by 0%
The Hydration Pharmaceuticals Company Limited (HPC)
ORDINARY FULLY PAID
 Consumer Staple $2 Notice of Extraordinary General Meeting/Proxy Form 2 Sep 2026 10:26AM $0.003 $0.003 fallen by 0%
The Hydration Pharmaceuticals Company Limited (HPC)
ORDINARY FULLY PAID
 Consumer Staple $2 Appendix 4D and FY26 Half Year Financial Report 31 Aug 2026 4:39PM $0.003 $0.003 fallen by 0%
The Hydration Pharmaceuticals Company Limited (HPC)
ORDINARY FULLY PAID
 Consumer Staple $2 Q2 FY26 Quarterly Activities Report (App 4C) 31 Jul 2026 2:14PM $0.004 $0.003 fallen by 25%

HPC Financial Summary

Year to Dec NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2025A -$4.11 -$1.10 -66.20% 0.00 0.00 0.00% 0.0%
2024A -$9.13 -$3.10 -29.80% 0.00 0.00 0.00% 0.0%
2023A -$11.85 -$4.50 -52.10% 0.00 0.00 0.00% 0.0%

HPC Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2023 A 2024 A 2025 A 2023 A 2024 A 2025 A 2023 A 2024 A 2025 A
The Hydration Pharmaceuticals Company Limited (HPC) $2M -0.6624 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%

HPC Market Comparison

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.00 0.00 0.61 0.00
Market 0.31 13.60 1.05 0.72
Sector 0.00 21.00 1.09 0.00

HPC Directors

Name Position Start Date
Mr Oliver Baker Chief Executive Officer, Managing Director 25 May 2024
Mr George Karafotias Non-Executive Director 16 Jun 2026
Ms Margaret Hardin Non-Executive Director 8 Feb 2022
Mr Nick Katiforis Non-Executive Director 24 Jun 2026
Mr Nicholas(Nick) Peter Berry Non-Executive Director, Non-Executive Chairman 25 May 2024

The Hydration Pharmaceuticals Company Limited (HPC) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
4 Jun 2025 CONSTABLE, Joseph Buy Direct Shares 142,857 $0.007 $999.999
4 Jun 2025 CONSTABLE, Joseph Buy Indirect Shares 752,531 $0.007 $5,267.717
22 Apr 2025 BERRY, Nick Issued Indirect Shares 12,190,424 $0.010 $121,904.240

See all changes in directors' interest & trades for The Hydration Pharmaceuticals Company Limited (HPC) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

HPC Management

Name Position
Victoria Nadalin Company Secretary

HPC Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in The Hydration Pharmaceuticals Company Limited (HPC). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
60,952,123 (19.99%) PURE Asset Management Pty Ltd
60,091,080 (16.20%) Constable Group
29,435,241 (7.68%) Woobinda Nominees Pty Limited
29,124,128 (6.84%) Regal Funds Management Pty Ltd
20,000,000 (5.22%) One Funds Management Ltd

HPC Calendar of Events

Date Event
30 August 2027 Report (Interim)
30 April 2027 Report (Annual)
26 February 2027 Report (Prelim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.